Original Research
Retail pharmacy prescription medicines’ availability, prices and affordability in Eswatini
Submitted: 19 March 2021 | Published: 15 September 2021
About the author(s)
Garikai Shambira, Discipline of Pharmaceutical Sciences, School of Health Sciences, University of KwaZulu-Natal, Durban, South AfricaFatima Suleman, Discipline of Pharmaceutical Sciences, School of Health Sciences, University of KwaZulu-Natal, Durban, South Africa
Abstract
Background: Limited availability of medicines in public facilities and unaffordable prices in the private sector act as barriers to medicines’ access. Patients in Eswatini may be forced to buy medicine from the private sector resulting from chronic medicines’ shortages in public health facilities. The extent to which they can afford to do so is unknown.
Aim: To determine the availability, price and affordability of medicines in the retail pharmacies in Eswatini, and to compare the results regionally and internationally.
Setting: Retail pharmacy sector in the four administrative regions of Eswatini.
Methods: Data on availability, price and affordability to patients for 50 medicines in the originator brand (OB) and the lowest priced generic (LPG) equivalent, were collated using the standardised World Health Organization/Health Action International methodology from 32 retail pharmacies in the four regions of Eswatini. Prices were then compared with selected countries.
Results: The overall mean availability of all medicines in selected retail pharmacies was 38.5%; standard deviation [s.d.] = 20.4% for OBs and 80.9%; s.d. = 19.0% for LPGs. The overall median price ratio (MPR) in the surveyed pharmacies was 18.61 for the OBs and 4.67 for LPGs. Most standard treatments with LPGs cost less than a day’s wages whilst for OBs cost more than a day’s wages. The differences between Eswatini and South African prices were statistically significant.
Conclusion: Drug pricing policies and price monitoring tools are needed for the whole pharmaceutical chain in Eswatini to monitor availability, affordability and accessibility of medicines to the general populace.
Keywords
Metrics
Total abstract views: 5229Total article views: 9506
Crossref Citations
1. Implementation of WHO-PEN interventions in Eswatini: an assessment of health equity and out-of-pocket expenditure for diabetes and hypertension care
Harsh Vivek Harkare, Ntombifuthi Ginindza, Lisa Stehr, Brianna Osetinsky, Michaela Theilmann, Lisa-Rufaro Marowa, Nyasatu Ntshalintshali, Till Bärnighausen, Fabrizio Tediosi
International Journal for Equity in Health year: 2026
doi: 10.1186/s12939-026-02829-8
2. Assessment of prices, availability and affordability of essential medicines in Juba County, South Sudan
Justin Deng, Augustino Ting Mayai, Egide Kayitare, Theoneste Ntakirutimana, Omary Swallehe, Thomas Bizimana
Journal of Pharmaceutical Policy and Practice vol: 16 issue: 1 year: 2023
doi: 10.1186/s40545-023-00675-5
3. Progress and Gaps in National Medicines Policy Implementation in SADC Member States: A Comprehensive Desktop Review
Ana Ribeiro, Sofia Martins, Teresa Fonseca
Interdisciplinary Research in Medical Sciences Specialty vol: 4 issue: 1 first page: 42 year: 2024
doi: 10.51847/0eVBxAI8y0
4. Evaluating the national system for rare diseases in China from the point of drug access: progress and challenges
Luyao Qiao, Xin Liu, Junmei Shang, Wei Zuo, Tingting Xu, Jinghan Qu, Jiandong Jiang, Bo Zhang, Shuyang Zhang
Orphanet Journal of Rare Diseases vol: 17 issue: 1 year: 2022
doi: 10.1186/s13023-022-02507-2


